Experimental drug shows promise for Tough-to-Treat prostate cancer

NCT ID NCT04754191

Ongoing Disease control Sponsor: University of Utah Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests enfortumab vedotin, a drug that targets cancer cells, alone or with other drugs in 34 men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if the drug can shrink tumors, lower PSA levels, or stabilize the disease for at least 6 months. The study is active but no longer recruiting new participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: enfortumab vedotin
What this could lead to: If successful, this could point toward a new treatment option for men with advanced prostate cancer that has stopped responding to standard therapies.
What could go wrong: This is a small, early-phase trial (34 people) with no control group, so results may not apply broadly. The drug may cause side effects like nerve damage or skin reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Huntsman Cancer Institute

Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.